

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN TECHNOLOGIES, INC.
Petitioner,

v.

NOVEN PHARMACEUTICALS, INC.
Patent Owner.

Patent No. 9,724,310

Title: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

Inter Partes Review No. IPR2018-00173

**PATENT OWNER'S UPDATED EXHIBIT LIST
AS OF SEPTEMBER 5, 2018**

EXHIBIT LIST

Ex #	Description
2001	Declaration of Dr. Adrian C. Williams
2002	<i>Curriculum Vitae</i> of Dr. Adrian C. Williams
2003	Minivelle® Product Label
2004	J. Hadgraft and R. Guy, <i>Feasibility Assessment in Topical and Transdermal Delivery</i> , in TRANSDERMAL DRUG DELIVERY 3-4 (R. Guy & J. Hadgraft eds., 2d ed. 2003)
2005	J. Hadgraft, <i>Passive enhancement strategies in topical and transdermal drug delivery</i> , 184 INT’L J. PHARMACEUTICS 1-6 (1999)
2006	B. Barry, <i>Transdermal Drug Delivery</i> , in AULTON’S PHARMACEUTICS – THE DESIGN AND MANUFACTURE OF MEDICINES 565, 571-72, 577 (M. Aulton ed., 3d ed. 2007)
2007	A. Williams & B. Barry, <i>Urea analogues in propylene glycol as penetration enhancers in human skin</i> , 36 INT’L J. PHARMACEUTICS 43-50 (1989)

Ex #	Description
2008	K. Brain & R. Chilcott, <i>Physicochemical Factors Affecting Skin Absorption</i> , in PRINCIPLES AND PRACTICE OF SKIN TOXICOLOGY 83-92 (R. Chilcott and S. Price eds., 2008)
2009	Esclim® Product Label
2010	J. Mantelle, <i>et al.</i> , <i>Effect of Silicone/Acrylic PSA Blends on Skin Permeation</i> , 26 PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS 415-16 (Rev. July 1999) (“the Mantelle Article”)
2011	A. Williams & B. Barry, <i>Chemical Permeation Enhancement</i> , in ENHANCEMENT IN DRUG DELIVERY 233, 248-50 (E. Touitou & B. Barry eds., 2007)
2012	A. Williams & B. Barry, <i>The enhancement index concept applied to terpene penetration enhancers for human skin and model lipophilic (oestradiol) and hydrophilic (5-fluorouracil) drugs</i> , 74 INT’L J. PHARMACEUTICS 157-168 (1991)
2013	K. Walters & K. Brain, <i>Dermatological Formulation and Transdermal Systems</i> , in DERMATOLOGICAL AND TRANSDERMAL FORMULATIONS 338-43 (K. Walters, ed., 2002)

Ex #	Description
2014	Google Scholar search results obtained March 7, 2018 – citations of Kim <i>et al.</i> , <i>Penetration Enhancement of β2-Selective Agonist, Tulobuterol, Across Hairless Mouse Skin</i> , J. Pharm. Invest. 33: 79-84 (2003), available online at https://scholar.google.com/scholar?cites=7903453726087495818&as_sdt=2005&scioldt=0,5&hl=en
2015	A. Ghosh <i>et al.</i> , <i>Current Pharmaceutical Design on Adhesive Based Transdermal Drug Delivery Systems</i> , 21 CURR. PHARM. DESIGN 2771-2783 (2015)
2016	U.S. Patent No. 8,029,820
2017	B. Godin & E. Touitou, <i>Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models</i> , 59(11) ADV. DRUG DELIV. REVIEWS 1152-1161 (2007)
2018	R. Hinz <i>et al.</i> , <i>In vitro percutaneous penetration: evaluation of the utility of hairless mouse skin</i> , 93(1) J. INVEST. DERMATOL. 87-91 (1989)
2019	J. Bond & B. Barry, <i>Hairless mouse skin is limited as a model for assessing the effects of penetration enhancers in human skin</i> , 90(6) J. INVEST. DERMATOL. 810-813 (1988)

Ex #	Description
2020	R. Subedi <i>et al.</i> , <i>Influence of formulation variable in transdermal drug delivery system containing zolmitriptan</i> , 419 INT’L J. PHARMACEUTICS 209-214 (2011)
2021	R. Subedi <i>et al.</i> , <i>Formulation and in vitro evaluation of transdermal drug delivery system for donezil</i> , 42 J. PHARMA. INVEST. 1-7 (2012)
2022	J. Mantelle, <i>DOT Matrix® Technology, in MODIFIED RELEASE DRUG DELIVERY TECHNOLOGY</i> 405-14 (Rathbone <i>et al.</i> eds., 2d ed. 2008) (“the Mantelle Chapter”)
2023	J. van de Sandt <i>et al.</i> , <i>In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study</i> , 39 REG. TOXICOL. PHARMACOL. 271–281 (2004)
2024	Binding Settlement Term Sheet between Petitioner and Patent Owner

Respectfully submitted,

/ Jason N. Mock /
Courtenay C. Brinckerhoff
Registration No. 37,288

Jason N. Mock
Registration No. 69,186

Foley & Lardner LLP
Counsel for Patent Owner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.